Neutrophil FcγRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis

被引:44
|
作者
Tse, WY [1 ]
Abadeh, S
Jefferis, R
Savage, COS
Adu, D
机构
[1] Queen Elizabeth Hosp, Dept Nephrol, Birmingham B15 2TH, W Midlands, England
[2] Univ Birmingham, Sch Med, Dept Immunol, Birmingham, W Midlands, England
来源
CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2000年 / 119卷 / 03期
关键词
Fc gamma RIIIb receptor; polymorphism; ANCA; systemic vasculitis;
D O I
10.1046/j.1365-2249.2000.01182.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neutrophils constitutively express Fc gamma RIIa and Fc gamma RIIIb receptors. Both receptors exhibit allelic variants which have different quantitative functional capacities: the biallelic Fc gamma RIIa-R131 and -H131 alleles, and the neutrophil antigen (NA) NA1/NA2 alleles. ANCA activation of neutrophils requires ligation of Fc gamma RIIa receptor, but recent data have shown that ANCA can also bind Fc gamma RIIIb receptor. The aim of this study was to determine whether the Fc gamma RIIIb polymorphism was a risk factor for the development of ANCA-associated systemic vasculitis, or the associated nephritis. Fc gamma RIIIb receptor genotyping was determined by allele-specific polymerase chain reaction. Genomic DNA was extracted from 101 Caucasian patients with ANCA(+) vasculitis (of whom 84 had renal disease) and 100 ethnically matched controls. Of the patients with ANCA(+) systemic vasculitis, 71 had ANCA with specificity for proteinase 3 and 30 with specificity for myeloperoxidase (MPO). Overall no significant difference in genotype distribution or allele frequencies was found between patients and controls, or between patients with renal disease and controls. However, there was a trend for an increase in homozygosity for the NA1 allele in patients with a vasculitis and this was significant in patients who had anti-MPO antibodies. The Fc gamma RIIIb receptor polymorphism is not a major factor predisposing to the development of ANCA(+) systemic vasculitis or the associated nephritis. The over-representation of the Fc gamma RIIIb homozygous NA1 allele in patients with anti-MPO antibodies may have implications for disease susceptibility.
引用
收藏
页码:574 / 577
页数:4
相关论文
共 50 条
  • [1] No association between neutrophil FcγRIIa allelic polymorphism and antineutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis
    Tse, WY
    Abadeh, S
    McTiernan, A
    Jefferis, R
    Savage, COS
    Adu, D
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1999, 117 (01): : 198 - 205
  • [2] Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis
    Thickett, DR
    Richter, AG
    Nathani, N
    Perkins, GD
    Harper, L
    RHEUMATOLOGY, 2006, 45 (03) : 261 - 268
  • [3] PROPYLTHIOURACIL INDUCED ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) VASCULITIS
    Lim, V.
    David, A.
    Toombes, S.
    Venuthurupalli, S.
    NEPHROLOGY, 2014, 19 : 95 - 95
  • [4] Anti-neutrophil cytoplasmic antibodies (ANCA) preferentially engage FcγRIIIb on neutrophils.
    Edberg, JC
    Kocher, M
    Fleit, H
    Kimberley, RP
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S243 - S243
  • [5] Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis
    Gencik, M
    Borgmann, S
    Zahn, R
    Albert, E
    Sitter, T
    Epplen, JT
    Fricke, H
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1999, 117 (02): : 412 - 417
  • [6] Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
    Alihosseini, Christopher
    Kopelman, Hannah
    Zaino, Mallory
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (12) : 1449 - 1454
  • [7] Rivaroxaban Induced Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
    Chopra, M.
    Cristan, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] LUNG PERFORMANCE OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) ASSOCIATED VASCULITIS
    Yan, Bingdi
    Hu, Yuxin
    Zhang, Qinghua
    Shi, Shaomin
    RESPIROLOGY, 2015, 20 : 84 - 84
  • [9] Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go?
    Kallenberg, C. G. M.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 164 : 1 - 3
  • [10] Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis
    Niles, J.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 164 : 27 - 30